| 刘玲玲,毛玉芳,黄爱萍,王平康,冯 娟.塞来昔布治疗类风湿性关节炎的临床疗效及其对血清CRP、RF水平的影响[J].现代生物医学进展英文版,2018,(21):4122-4125. |
| 塞来昔布治疗类风湿性关节炎的临床疗效及其对血清CRP、RF水平的影响 |
| Clinical Effect of Celecoxib on Rheumatoid Arthritis and Serum Levels of C-reactive Protein and Rheumatoid Factor |
| Received:February 26, 2018 Revised:March 21, 2018 |
| DOI：10.13241/j.cnki.pmb.2018.21.027 |
| 中文关键词: 塞来昔布 类风湿性关节炎 C反应蛋白 类风湿因子 |
| 英文关键词: Celecoxib Rheumatoid arthritis C-reactive protein Rheumatoid factor |
| 基金项目:四川省卫生厅科研基金项目(140817) |
|
| Hits: 470 |
| Download times: 217 |
| 中文摘要: |
| 摘要 目的：研究塞来昔布治疗类风湿性关节炎的临床评价及其对患者血清C反应蛋白(CRP)、类风湿因子(RF)水平的影响。方法：选取2014年9月至2015年8月本院收治的84例类风湿关节炎患者，按照随机数字法分为观察组和对照组，每组42例。对照组采取常规方案进行治疗，观察组患者在对照组治疗基础上加以塞来昔布进行治疗。比较两组患者治疗前和治疗后CRP、RF、白介素-1(IL-1)、白介素-6(IL-6)水平的变化、临床疗效和不良反应的发生情况。结果：治疗后，观察组患者的总有效率、患者的自评疗效总有效率均显著高于对照组(P<0.05)。治疗前，两组患者血清CRP、RF、IL-1、IL-1、IL-6水平比较差异无统计学意义(P>0.05)；治疗后，两组患者血清CRP、RF、IL-1、IL-1、IL-6水平均较治疗前显著降低(P<0.05)，且观察组的血清CRP、RF、IL-1、IL-1、IL-6水平显著低于对照组(P<0.05)。此外，观察组的不良反应率显著低于对照组(P<0.05)。结论：塞来昔布能显著提高类风湿性关节炎患者的临床疗效，且安全性较高，可能与其有效降低血清CRP、RF水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the clinical effect of celecoxib in the treatment of rheumatoid arthritis and its influence on the serum levels of C-reactive protein (CRP) and rheumatoid factor (RF). Methods: 84 patients with rheumatoid arthritis who were treated in our hospital from September 2014 to August 2015 were selected and randomly divided into the observation group and the control group. The patients in the control group were treated with conventional regimen, while the patients in the observation group were treated with celecoxib on the basis of the control group. Then the serum levels of CRP, RF, IL-1 and IL-6, clinical efficacy and side effects were ob- served and compared between the two groups before and after the treatment. Results: After treatment, the total effective rate in the obser- vation group was significantly higher than that of the control group(P<0.05). After treatment, the self-evaluation of observation group was significantly higher than that of the control group (P <0.05). There was no significant difference in the serum levels of CRP, RF, IL-1 and IL-6 between the two groups before the treatment (P>0.05). After treatment, the serum levels of CRP, IL-1 and IL-6 in the observation group were significantly lower than those of the control group (P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that of the control group (P<0.05). Conclusion: Celecoxib could effectively enhance the clinical effect and safety of patients with rheumatoid arthritis, which might be related to the reduction of the serum levels of CRP and RF. |
|
View Full Text
View/Add Comment Download reader |
| Close |
